Jason Yang MD, PhD

Dr. Jason Yang Joined Cstone Pharmaceuticals In 2016, as Its Chief Medical Officer (CMO). He Has Over 25 Years of Global Experience in Biomedical Research and Clinical Development of Oncology Drugs.

Prior to Joining Cstone, Dr. Jason Yang Served as the Senior Vice President and Head of Clinical Development at Beigene Since 2014. He and His Team Generated Key Safety and Proof of Concept Efficacy Data That Supported Beigene’s Two Successful Financing Rounds in 2014 and 2015, the Ipo, and a Follow-on Offering in the Us Nasdaq Market in 2016. Prior to Joining Beigene, Dr. Yang Served as Oncology Medical Director at Covance, Senior Principal Scientist in Oncology Translational Biomarkers at Pfizer, and Research Scientist in Cancer Genomics at Tularik/Amgen.

Throughout His Career, Dr. Yang Has Made Significant Contributions to the Successful Development of Several Anticancer Drugs. He Is Also the Author of Over 30 Publications and the Inventor of 9 Patents. In 2015, He Is Honored as a “distinguished Expert” by the Beijing “haiju Program.”

Dr. Yang was trained as a physician at Hubei Medical College and Nanjing Medical University. He then received his PhD training with Nobel Laureates Drs. Mike Brown and Joseph Goldstein at the University of Texas Southwestern Medical Center at Dallas. He completed his postdoctoral training with Dr. Stuart Schreiber at Harvard University.